These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22343966)

  • 41. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
    Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
    [No Abstract]   [Full Text] [Related]  

  • 43. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P; Parnis F; Gurney H
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate cancer: score one for validated targets.
    Bates SE
    Clin Cancer Res; 2011 Jun; 17(12):3866. PubMed ID: 21680541
    [No Abstract]   [Full Text] [Related]  

  • 46. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M; Petrylak DP
    Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
    Nandha R
    J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging treatments for castrate-resistant prostate cancer.
    Redding MB; Surati M
    J Pharm Pract; 2011 Aug; 24(4):366-73. PubMed ID: 21984773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cabazitaxel in prostate cancer: stretching a string.
    Dorff TB; Quinn DI
    Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
    [No Abstract]   [Full Text] [Related]  

  • 51. FDA approves prostate cancer treatment that inhibits testosterone synthesis.
    Thompson CA
    Am J Health Syst Pharm; 2011 Jun; 68(11):960. PubMed ID: 21593221
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Name that prostate cancer drug.
    Gomella LG
    Can J Urol; 2011 Jun; 18(3):5666. PubMed ID: 21703036
    [No Abstract]   [Full Text] [Related]  

  • 54. Abiraterone and castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
    [No Abstract]   [Full Text] [Related]  

  • 55. New therapeutic agents for castration-refractory prostate cancer.
    Patten DY; Sartor O
    Clin Genitourin Cancer; 2009 Aug; 7(2):E4-6. PubMed ID: 19692323
    [No Abstract]   [Full Text] [Related]  

  • 56. Cabazitaxel: a new drug for metastatic prostate cancer.
    Bilusic M; Dahut WL
    Asian J Androl; 2011 Mar; 13(2):185-6. PubMed ID: 21151153
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.
    Francini E; Petrioli R; Fiaschi AI; Laera L; Roviello G
    Medicine (Baltimore); 2014 Dec; 93(27):e163. PubMed ID: 25501058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cabazitaxel for prostate cancer: patient preparation and ongoing care.
    Hardwick J
    Br J Nurs; 2012 May 10-23; 21(9):S13-7. PubMed ID: 22690408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
    Peppercorn J; Armstrong A; Zaas DW; George D
    Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.